{"id":1439,"date":"2020-04-14T01:27:43","date_gmt":"2020-04-14T01:27:43","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1439"},"modified":"2026-02-24T00:11:33","modified_gmt":"2026-02-24T00:11:33","slug":"identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/","title":{"rendered":"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao)"},"content":{"rendered":"<p>Mutations in a cancer-related gene called <em>RET<\/em> were mainly found in certain cancers such as thyroid cancer. By analyzing large-scale DNA sequencing data from 37,056 cancer patients, we discovered <em>RET<\/em> mutations in multiple other cancers, mostly at low frequencies. In addition, we identified several novel <em>RET<\/em> mutations that can drive tumor formation, and some newly developed RET inhibitor drugs are able to effectively inhibit these <em>RET<\/em> mutations. Therefore, comprehensively charactering tumor-related <em>RET<\/em> mutations help better stratify cancer patients based on individual mutation status. Furthermore, patients with <em>RET<\/em> activating mutations could potentially benefit from the recent clinical development of RET-specific inhibitors and treat with more personalized therapeutic regimens. (<a href=\"https:\/\/jmg.bmj.com\/content\/early\/2020\/04\/13\/jmedgenet-2019-106546\">https:\/\/jmg.bmj.com\/content\/early\/2020\/04\/13\/jmedgenet-2019-106546<\/a> )<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mutations in a cancer-related gene called RET were mainly found in certain cancers such as thyroid cancer. By analyzing large-scale DNA sequencing data from 37,056 cancer patients, we discovered RET mutations in multiple other cancers, mostly at low frequencies. In addition, we identified several novel RET mutations that can drive tumor formation, and some newly [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1439","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Mutations in a cancer-related gene called RET were mainly found in certain cancers such as thyroid cancer. By analyzing large-scale DNA sequencing data from 37,056 cancer patients, we discovered RET mutations in multiple other cancers, mostly at low frequencies. In addition, we identified several novel RET mutations that can drive tumor formation, and some newly [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-14T01:27:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T00:11:33+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/04\\\/14\\\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/04\\\/14\\\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao)\",\"datePublished\":\"2020-04-14T01:27:43+00:00\",\"dateModified\":\"2026-02-24T00:11:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/04\\\/14\\\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\\\/\"},\"wordCount\":131,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/04\\\/14\\\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/04\\\/14\\\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/04\\\/14\\\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\\\/\",\"name\":\"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2020-04-14T01:27:43+00:00\",\"dateModified\":\"2026-02-24T00:11:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/04\\\/14\\\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/04\\\/14\\\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/04\\\/14\\\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/","og_locale":"en_US","og_type":"article","og_title":"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao) - JMG Contact blog","og_description":"Mutations in a cancer-related gene called RET were mainly found in certain cancers such as thyroid cancer. By analyzing large-scale DNA sequencing data from 37,056 cancer patients, we discovered RET mutations in multiple other cancers, mostly at low frequencies. In addition, we identified several novel RET mutations that can drive tumor formation, and some newly [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/","og_site_name":"JMG Contact blog","article_published_time":"2020-04-14T01:27:43+00:00","article_modified_time":"2026-02-24T00:11:33+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao)","datePublished":"2020-04-14T01:27:43+00:00","dateModified":"2026-02-24T00:11:33+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/"},"wordCount":131,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/","url":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/","name":"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2020-04-14T01:27:43+00:00","dateModified":"2026-02-24T00:11:33+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/04\/14\/identifying-novel-oncogenic-ret-mutations-and-characterising-their-sensitivity-to-ret-specific-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors (Contributed by Dr. Yu Yao)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1439"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1439\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}